This guideline covers the care and support of adults receiving social care in their own homes, residential care and community settings. It aims to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care.
This guideline covers good practice for managing medicines in care homes. It aims to promote the safe and effective use of medicines in care homes by advising on processes for prescribing, handling and administering medicines. It also recommends how care and services relating to medicines should be provided to people living in care homes.
This guideline covers planning and delivering social care and support for older people who have multiple long-term conditions. It promotes an integrated and person-centred approach to delivering effective health and social care services.
This guideline covers the transition between inpatient hospital settings and community or care homes for adults with social care needs. It aims to improve people's experience of admission to, and discharge from, hospital by better coordination of health and social care services.
This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition by improving the way it’s planned and carried out. It covers both health and social care.
This guideline covers the planning and delivery of person-centred care for older people living in their own homes (known as home care or domiciliary care). It aims to promote older people's independence and to ensure safe and consistently high quality home care services.
This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.
This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.
This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.
This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.
Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene..
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type IVa (MPS IVA)
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies (confirmed biallelic RPE65 gene mutations)
Evidence-based recommendations on culizumab (Soliris) for treating atypical haemolytic uraemic syndrome (aHUS)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children
Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency (ADA–SCID)
NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy
Evidence-based recommendations on HealOzone (ozone-releasing device) for treating tooth decay (occlusal pit/fissure caries/root caries)
Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block
Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Evidence-based recommendations on ipilimumab (YERVOY) for treating previously untreated advanced (unresectable or metastatic) melanoma (skin cancer)
Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)
Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes
Evidence-based recommendations on rituximab (MabThera) for first-line maintenance treatment of follicular non-Hodgkin's lymphoma
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism (VTE) after total hip or knee replacement in adults
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer..
Evidence-based recommendations on the use of Riluzole (Rilutek) for treating motor neurone disease (MND)
Evidence-based recommendations on imatinib (Glivec) for treating unresectable (inoperable) and/or metastatic gastrointestinal stromal tumours (GISTs)
Evidence-based recommendations on bevacizumab (Avastin) with oxaliplatin and fluorouracil plus folinic acid or capecitabine for metastatic colorectal cancer
NICE is unable to make a recommendation about the use in the NHS of temsirolimus for treating relapsed or refractory mantle cell lymphoma because no evidence
Evidence-based recommendations on trastuzumab (Herceptin) for treating adenocarcinoma (HER2-positive metastatic gastric cancer/stomach cancer)
Evidence-based recommendations on botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel
Evidence-based recommendations on lapatinib (Tyverb) or trastuzumab (Herceptin) combined with an aromatase inhibitor for the first-line treatment of..
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women
Evidence-based recommendations on peginterferon alfa (2a [Pegasys] or 2b [ViraferonPeg]) and ribavirin (Copegus or Rebetol) for treating chronic hepatitis C
Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis
Evidence-based recommendations on Pharmalgen (ALK-Abelló) for treating bee and wasp venom allergy
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis